BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Brilinta (Ticagrelor) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Brilinta (Ticagrelor)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04937699-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brilinta (Ticagrelor): Phase 4 readout est. (NCT04937699)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 4\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Sequential MonotherApy of TicagrElor and Clopidogrel Af
 ter Coronary Intervention\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04937699
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228456-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brilinta (Ticagrelor): Phase 4 readout est. (NCT06228456)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 4\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Effects of Low-dose Ticagrelor vs. Clopidogrel in Stabl
 e Patients Undergoing Elective Percutaneous Coronary Intervention\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06228456
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05997693-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT05997693)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3.\nStudy: One-Month DAPT in CABG
  Patients\nEstimated primary completion: January 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05997693
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04755387-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Brilinta (Ticagrelor): Phase 4 readout est. (NCT04755387)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 4.\nStudy: Ticagrelor De-escalati
 on Strategy in AMI Patients\nEstimated primary completion: 15 January 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04755387
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05047172-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT05047172)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3.\nStudy: Comparison of Anti-coa
 gulation and Anti-Platelet Therapies for Intracranial Vascular Atherosteno
 sis\nEstimated primary completion: 31 January 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05047172
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06981390-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Brilinta (Ticagrelor): Phase na readout est. (NCT06981390)
DESCRIPTION:Brilinta (Ticagrelor)\, phase na\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: Ticagrelor-Based Dual Antiplatelet Therapy Duration in
  CABG\nEstimated primary completion: 20 February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06981390
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438886-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Brilinta (Ticagrelor): Phase 1 readout est. (NCT07438886)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 1.\nStudy: Catequentinib Hydrochl
 oride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers\nEstimate
 d primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07438886
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613840-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:Brilinta (Ticagrelor): Phase na readout est. (NCT07613840)
DESCRIPTION:Brilinta (Ticagrelor)\, phase na\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: Personalizing Thromboprophylaxis for Patients With Per
 ipheral Artery Disease\nEstimated primary completion: 29 April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07613840
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06853535-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT06853535)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3\, Acute Ischemic Stroke.\nStudy
 : Precision Antiplatelet Therapy Guided by Platelet Aggregation Function i
 n Patients With Acute Ischemic STROKE\nEstimated primary completion: 30 Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06853
 535
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05283356-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Brilinta (Ticagrelor): Phase 4 readout est. (NCT05283356)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 4.\nStudy: Single Antiplatelet Tr
 eatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implan
 tation\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05283356
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06714526-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Brilinta (Ticagrelor): Phase na readout est. (NCT06714526)
DESCRIPTION:Brilinta (Ticagrelor)\, phase na\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: Effect of Genotype-Guided Oral P2Y12 Inhibitor Selecti
 on vs Conventional Clopidogrel Therapy in Symptomatic ICAD\nEstimated prim
 ary completion: August 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ticagrelor#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06714526
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05476991-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT05476991)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Evaluation of Low Dose Colchicine and Ticagrelor in Pre
 vention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis\
 nEstimated primary completion: 1 September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05476991
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07080684-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brilinta (Ticagrelor): Phase 4 readout est. (NCT07080684)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 4\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Short-Term Dual Antiplatelet Therapy With Early Transi-
 tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Cor
 onary Artery Disease\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07080684
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582835-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT07582835)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Study of the Long-term Effects of P2Y12 Inhibitor Monot
 herapy and Coagulation Markers After Percutaneous Coronary Angioplasty.\nE
 stimated primary completion: April 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07582835
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06451198-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brilinta (Ticagrelor): Phase 4 readout est. (NCT06451198)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 4\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: IndObufen Versus asPirin After Coronary Drug-eluting St
 ent implantaTION in Elderly Patients With Acute Coronary Syndrome\nEstimat
 ed primary completion: 31 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06451198
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932639-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Brilinta (Ticagrelor): Phase 4 readout est. (NCT07932639)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 4.\nStudy: Long-Term Sequential D
 ual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial A
 rterial Stenosis\nEstimated primary completion: 28 February 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07932639
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507500-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Brilinta (Ticagrelor): Phase 4 readout est. (NCT07507500)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 4.\nStudy: Dual Antiplatelet Ther
 apy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel
  vs Ticagrelor & 12 Months vs 1-3 Months\nEstimated primary completion: Ju
 ly 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07507
 500
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821008-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20291214
DTEND;VALUE=DATE:20291215
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT07821008)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3.\nStudy: TicAgreLor Versus Plac
 ebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blin
 ded Randomised Controlled Study\nEstimated primary completion: 14 December
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0782100
 8
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257198-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT07257198)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3.\nStudy: Aspirin-free Strategy 
 With Ticagrelor in Patients With a Myocardial Infarction Treated Medically
  Alone\nEstimated primary completion: 1 January 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07257198
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822620-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Brilinta (Ticagrelor): Phase na readout est. (NCT07822620)
DESCRIPTION:Brilinta (Ticagrelor)\, phase na.\nStudy: Ticagrelor Hemoadsorp
 tion Using Cytosorb® for Reduction of Bleeding During Cardiac Surgery\nEs
 timated primary completion: March 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07822620
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911124-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Brilinta (Ticagrelor): Phase 2 readout est. (NCT07911124)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 2.\nStudy: Ticagrelor for Inflamm
 ation and Cardiovascular Risk in Patients With Chronic Kidney Disease\nEst
 imated primary completion: December 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07911124
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07844603-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Brilinta (Ticagrelor): Phase 2 readout est. (NCT07844603)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 2\, Acute Ischemic Stroke.\nStudy
 : Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thromb
 ectomy and/or Intravenous Thrombolysis (CoPRIME)\nEstimated primary comple
 tion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ticagrelor#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07844603
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06352632-6104@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20340930
DTEND;VALUE=DATE:20341001
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT06352632)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3.\nStudy: ACT-GLOBAL Adaptive Pl
 atform Trial for Stroke\nEstimated primary completion: September 2034. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06352632
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
